Feed ZEOX
Summary
30 / 100 · Bulios Score
Valuation 50Growth 0Profitability 20Quality 21Debt 56Stability 40
What speaks for it
- It holds more cash than debt: $1.85M against $96.0K.
What to watch
- The company made a loss over the last 12 months.
- Revenue fell by 7.1% a year over the last 3 years.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedThe company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
20212022202320242025
Diluted EPS (USD)
20212022202320242025
Revenue grew by 11% a year over 5 years. Over the last 3 years it fell by 7.1% a year.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $3.88M.
Profitability in detailIs it financially healthy?
YesCash and short-term investments $1.85M
Debt $96.0K
Free cash flow over 12 months -$1.35M
Over the last 12 months it spent more cash than it brought in. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
Fiscal year 2018By product
- Patient Referral and Product Sales 100%
By region
The company reports no revenue by region.
Patient Referral and Product Sales brings in 100% of revenue.
Segments in detail